For a long-time user of snus or nicotine pouches, the familiar burn is often a sign of the product working. But for Bengt Wiberg, that sensation was a problem to be solved. His personal experience with gum irritation led him to invent a new kind of pouch, one with a built-in barrier designed to protect oral tissue from the high pH and flavorings inside. A decade later, that invention is the core of Stingfree AB, a Swedish company betting that comfort can be a competitive edge in the massive market for oral nicotine [Perplexity Sonar Pro Brief, Unknown].
Stingfree’s proposition is straightforward: a patented pouch construction where one side features an integrated, non-woven shield. The company calls this technology PROTEX. In practice, it means the blue side of the pouch faces the user’s gum, acting as a physical barrier against the ingredients that commonly cause stinging and lesions. The other side of the pouch remains permeable, allowing nicotine and flavor to be released as usual [Sting Free, Unknown]. It’s a hardware innovation for a consumable product, aiming to address a well-documented side effect without altering the user’s experience of the nicotine dose itself.
The wedge is a physical patent
The company’s primary wedge is intellectual property. Its patent covers portion pouches "where one side has an integrated protection for the gums, regardless of whether they are filled with tobacco or plant fibers" [Perplexity Sonar Pro Brief, Unknown]. This allows Stingfree to operate on two tracks. First, it sells its own branded line of tobacco-free nicotine pouches in flavors like Strong Blue Mint and Swedish Cola, primarily in Sweden and Austria and via global online retailers [Reddit, 2025]. Second, and more strategically, it seeks to license the PROTEX technology to other manufacturers in the smokeless tobacco and nicotine pouch industry. The vision is to make the shielded pouch a standard feature, akin to a filter on a cigarette, rather than just a niche brand.
This B2B licensing model is classic platform thinking applied to a regulated consumable. If successful, Stingfree would collect a royalty on every licensed pouch sold, embedding itself into the supply chain of much larger companies. The early validation for this pitch comes not from a major partnership announcement, but from a clinical observation. The company cites a study where dentists who were previous snus users and had reported moderate or severe gum lesions used Stingfree products; afterward, no such lesions were present [Sting Free, Unknown]. For an industry increasingly scrutinized for health impacts, that kind of claim is a potential differentiator.
A board built for credibility and scale
The team assembled to execute this plan leans heavily on Swedish industrial and regulatory credibility. Founder and inventor Bengt Wiberg remains the public face and president, frequently appearing on podcasts and at conferences to discuss harm reduction and oral health [2FIRSTS, January 2026]. Day-to-day leadership falls to CEO Daniel Wiberg [Bolagsfakta, Unknown]. The board and investor group, however, signals a reach beyond the startup scene.
| Name | Role / Background | Relevance to Stingfree |
|---|---|---|
| Erik Selin | Swedish billionaire real estate investor, CEO of Balder | Lead investor; provides significant capital and business network [MyNewsdesk, Unknown] |
| Meg Tivéus | Former CEO of state-owned gambling firm Svenska Spel | Brings experience scaling regulated consumer products and corporate governance [Perplexity Sonar Pro Brief, Unknown] |
| Curt Enzell | Former scientist at Swedish National Institute of Public Health | Adds scientific and public health credibility, particularly in tobacco research [Perplexity Sonar Pro Brief, Unknown] |
| Andy Cars | Serial entrepreneur, runs Lean Ventures International | Joined the board to help structure and streamline innovation work [Sting Free, Unknown] |
This group has helped the company secure a total of roughly $3.53 million in funding to date, with a new share issue noted in 2024 to support commercialization [CB Insights, Unknown] [Stingfree, 2024]. The presence of figures like Selin and Tivéus suggests backers are looking at this as more than a niche consumer brand; they are betting on the technology’s applicability across an entire product category.
Navigating a market in regulatory flux
The global market for nicotine pouches is growing rapidly as smokers seek alternatives, but it exists in a complex regulatory environment. In Europe, regulations are tightening, with debates ongoing about flavors, nicotine strengths, and health warnings. Stingfree’s positioning is inherently aligned with a harm reduction narrative, which could be advantageous. Founder Bengt Wiberg has been active in these policy discussions, arguing for a science-based approach that recognizes relative risks [TobaccoIntelligence, Unknown].
The company’s technology does not change the nicotine content or addictive potential of the product. Instead, it addresses a localized adverse effect. This creates a clear, if narrow, lane for the company: it can market itself as improving the safety profile of existing products without challenging the fundamental regulatory classification of those products. For potential licensing partners, this could be a way to mitigate one common consumer complaint and potentially align with evolving expectations for product stewardship.
The risks in the rollout
For all its patented cleverness, Stingfree’s path is fraught with the classic challenges of introducing a new standard into an established, slow-moving industry. The company’s success hinges on convincing large, entrenched manufacturers to alter their pouch production processes to incorporate PROTEX. This requires them to see sufficient consumer demand for gum protection to justify the operational change and any associated licensing cost. To date, no major licensing deal has been publicly announced.
The competitive landscape is also opaque but formidable. While no direct competitor with an identical gum-shield technology is named in sources, the large tobacco and nicotine companies that control the market have immense R&D budgets. They could develop their own solutions in-house if the consumer need becomes pronounced. Stingfree’s first-mover advantage and patent portfolio are its primary defenses here.
Finally, the company’ own-brand sales, while a proof of concept, face the brutal economics of direct-to-consumer nicotine products, which are marketing-intensive and compete on flavor, price, and brand loyalty. Stingfree’s long-term valuation will likely be determined by the licensing business, not its pouch sales.
What the next year must show
The coming twelve months are critical for Stingfree to transition from an interesting innovator to a commercial partner. The key milestone to watch is the signing of a first major licensing agreement with a recognized manufacturer of snus or nicotine pouches. Such a deal would validate the B2B model and provide a concrete revenue stream beyond direct sales. The company may also need to raise additional capital to fund business development efforts and potentially navigate regulatory submissions in new markets, though its current investor base appears capable of supporting further rounds.
The company is targeting a specific, often overlooked patient population: habitual users of oral nicotine products who experience gingival irritation, a condition sometimes referred to as snus keratosis or nicotine stomatitis. For these users, the standard of care today is essentially palliative or behavioral,using lower-strength products, rotating the pouch placement, practicing rigorous oral hygiene, or, ultimately, cessation. Stingfree’s proposition is that a material science intervention at the point of contact can allow continued use without the collateral damage to oral mucosa. It’s a small but meaningful shift in the harm reduction toolkit, one that treats a product’s local side effect as a solvable engineering problem rather than an inevitable trade-off.